Market revenue in 2023 | USD 435.2 million |
Market revenue in 2030 | USD 656.7 million |
Growth rate | 6.1% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 65.76% in 2023. Horizon Databook has segmented the France blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The studies report that there are around 35,000 new cases of blood cancer diagnosed annually in France, with leukemia accounting for around 30% of these cases. In September 2023, Cancer Research UK and the French National Cancer Institute (INCa) signed a new scientific partnership to collaborate on cancer research and improve patient outcomes.
The partnership aimed to share knowledge and expertise in cancer research & treatment, develop new treatments & therapies, and enhance international cooperation & collaboration, address common cancer challenges, such as increasing cancer incidence, and improve patient access to innovative treatments.
In May 2022, THERADIAG France launched two additional kits in its i-Tracker tests range, expanding its portfolio of tests for monitoring biologic treatments. The new kits are i-Tracker Certolizumab and i-Tracker Anti-Certolizumab.
Horizon Databook provides a detailed overview of country-level data and insights on the France blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into France blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account